SWOG clinical trial number
SWOG-9323 (E4592)
Laboratory/Clinical Correlative Studies in Non-Small Cell Lung Cancer: Ancillary Study to SWOG-9252 (INT-0115, E3590, RTOG-91-05, NCCTG 91-24-51)
Closed
Phase
Published
Abbreviated Title
Laboratory/Clinical Correlative Studies in Non-Small Cell Lung Cancer: Ancillary Study to SWOG-9252 (INT-0115, E3590, RTOG-91-05, NCCTG 91-24-51)
Activated
03/01/1994
Closed
12/01/1996
Research committees
Lung Cancer
Publication Information Expand/Collapse
2001
Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a lab ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postop adjuvant therapy
1999
Prognostic significance of p53 and K-RAS mutations in primary resected non-small cell lung cancer: Preliminary results from a propsective randomized trial of postoperative adjuvant therapy (intergroup trial 0115).
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/EA5231
A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
SWOG Clinical Trial Number
S2414
INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/A082304/S2402
Perioperative Versus Adjuvant Systemic Therapy In Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG, CTIU2317
Research Committee(s)
Lung Cancer
Activated
12/11/2024
Open